RegionInternational. Neutral scientific reference — not offered for sale here.
Cart · 0
Set region
Explore  /  Matrixyl (Palmitoyl Pentapeptide-4)
Research reference — not for sale

Matrixyl (Palmitoyl Pentapeptide-4)

B
lead outcome
Topical: appearance of photoaged skin (fine…
grades vary by outcome ↓
Peptide
also called — Matrixyl® (trade name, Sederma / Croda) · INCI: Palmitoyl Pentapeptide-4 · Pal-KTTKS · Palmitoyl Oligopeptide (older INCI, Matrixyl-family peptides) · formerly "Palmitoyl Pentapeptide-3" (pre-2006) · Palmitoyl-Lys-Thr-Thr-Lys-Ser
skin appearance (cosmetic)fine lines & wrinkles(reference:) collagen/ECM signalling

Cosmetic signal peptide — a different archetype from Argireline. Argireline is a neuromodulator (proposed to relax muscle); Matrixyl is a matrikine / signal peptide (proposed to tell skin to build matrix). It is the best-evidenced of the common cosmetic peptides — and its whole marketing ("collagen-boosting") is the claim trap.

In brief

Matrixyl (INCI Palmitoyl Pentapeptide-4) is a synthetic signal peptide — a palmitoylated fragment (Pal-KTTKS) of type I procollagen — used in anti-ageing cosmetics. It has the most-replicated clinical evidence among cosmetic signal peptides, anchored by a 12-week split-face RCT, showing a modest improvement in the appearance of photoaged skin. Many of the larger figures quoted for it (e.g. "+117% collagen") come from in-vitro or manufacturer data, not the controlled human trial.

Legal standing, by region
European Union
Lawful cosmetic

a lawful cosmetic ingredient (EU Regulation (EC) 1223/2009; US cosmetic law), sold over-the-counter worldwide. No injectable or "research" lane, no drug filing. Straightforwardly sellable as a cosmetic — the constraint is the claims.

Evidence, by outcome
How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade
Topical: appearance of photoaged skin (fine lines, wrinkle depth, roughness)
Best-evidenced cosmetic peptide of this set, but effect is modest; single main RCT; small
Robinson 2005 — 12-week split-face, double-blind, vehicle-controlled RCT, n=93 · Statistically significant improvement vs placebo
B
ECM synthesis in vitro (collagen I/III, fibronectin, HA; MMP-1↓, TIMP-1↑)
In vitro; the eye-catching "+117%/+327%" figures are cell-culture, not human outcomes
Fibroblast assays at ~3 ppm · Substantial stimulation
B
Comparable to retinol
Not equivalent to prescription retinoids; comparison is to low-concentration retinol
Some measures vs low-dose retinol (~0.07%) · Comparable on select endpoints, far gentler
C
Skin penetration at cosmetic doses
Better than plain KTTKS, but a formal 1–50 ppm dose study is lacking
Efficacy seen at 3–5 ppm; formal dose-escalation not published · Palmitoyl tail improves penetration
"Collagen-boosting" collagen synthesis in human skin
The 12-week vehicle-controlled human trial measured appearance — fine lines, wrinkle depth, roughness — not collagen synthesis in skin; the collagen mechanism itself rests on fibroblast culture
Marketing claim
D
"+117% collagen" the quoted magnitude
The +117% figure is a fibroblast cell-culture readout, not a human result. The human data is a single unreplicated manufacturer-run biopsy study showing raised collagen and elastin markers over about four months of twice-daily use — the right direction, well short of the quoted magnitude
Marketing claim
D
Safety (topical)
Non-irritating; suitable for sensitive skin
Broad cosmetic use · Well tolerated; no photosensitivity
Disclosure

Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.

Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.

Evidence changes

Get notified if this changes

We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for Matrixyl (Palmitoyl Pentapeptide-4) changes - nothing else.

One ingredient, one purpose. No marketing, no sharing. Unsubscribe anytime. See our privacy policy.

Cosmetic claims boundary
✓ Allowed (appearance / feel)
  • for the **appearance** of firmer, plumper, smoother skin
  • helps reduce the **look** of fine lines and wrinkles
  • supports a more youthful-looking complexion
✕ Not allowed (medicinal)
  • boosts / stimulates / increases **collagen** (synthesis/production)
  • collagen-boosting
  • rebuilds collagen
  • by function
  • wound healing
  • repairs
  • regenerates
  • the proposed mechanism

The medicinal-sounding science stays in the reference section; product copy speaks only to appearance/feel (Reg 655/2013). Different fields, never merged.

Identity

a synthetic lipopeptide — the pentapeptide KTTKS (5 amino acids, < 40 aa → peptide), a matrikine fragment of the C-terminal propeptide of type I procollagen, conjugated to palmitic acid (C16) to aid skin penetration (unmodified KTTKS is hydrophilic, ~562 Da, and penetrates poorly). KTTKS identified 1993 (Katayama); Matrixyl launched 2000 by Sederma.

Development & history

  • The active KTTKS sequence was identified in 1993 (Katayama et al.) as a collagen-propeptide fragment that stimulates matrix synthesis. To make it usable on skin, the French active-ingredient house Sederma attached a palmitoyl tail and launched Pal-KTTKS as Matrixyl in 2000 — described as the first peptide active designed for anti-ageing cosmetics (Lintner & Peschard, 2000).
  • The line then expanded commercially: Matrixyl → Matrixyl 3000 (a two-peptide system) → Matrixyl Synthe'6. Sederma is part of Croda. Like Argireline, it has only ever been a cosmetic ingredient, not a drug.

Variants

  • Matrixyl = single peptide Pal-KTTKS (Palmitoyl Pentapeptide-4).
  • Matrixyl 3000 = two-component: Palmitoyl Tripeptide-1 (Pal-GHK) (sometimes listed under the older INCI name Palmitoyl Oligopeptide) + Palmitoyl Tetrapeptide-7 (Pal-GQPR) — different signals (collagen + IL-6 downregulation).
  • Matrixyl Synthe'6 = Palmitoyl Tripeptide-38.

Mechanism (as proposed)

KTTKS is a matrikine — a fragment released during type I collagen processing that acts as a feedback signal. Matrixyl is proposed to mimic this signal: once the palmitoyl tail carries it into the dermis, KTTKS is proposed to bind fibroblast surface receptors (TGF-β-linked signalling) and stimulate extracellular-matrix synthesis (collagen, fibronectin, HA), with the effect described as self-limiting. Much of this is characterised in vitro; the extent and consistency of the effect on intact human skin is more modest than the cell-culture figures suggest.

Related reading

The anti-inflammatory side of the Matrixyl 3000 blend — its Palmitoyl Tetrapeptide-7 component and its "inflammaging" role — sits alongside the other soothing peptides in our anti-inflammatory peptides reference list. For how signal peptides like Matrixyl fit into a routine — layering, timing, and spotting a well-formulated product — see how to use peptides. For where Matrixyl ranks among the cosmetic peptides by evidence, see cosmetic peptides ranked by evidence and the dedicated Matrixyl explainer.

Scan your productSee if Matrixyl (Palmitoyl Pentapeptide-4) is in what you're usingOpen the scanner →
Chemical identifiers

Cross-reference identifiers for the authoritative external databases — not a recipe, and nothing about how to use it.

PubChem CID9897237
InChIKeyWSGCRSMLXFHGRM-DEVHWETNSA-N
SMILESCCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)O
UNIIKK181SM5JG

via PubChem exact-name match (Matrixyl) · high confidence

Sources — 5 cited
01Robinson LR, Fitzgerald NC, Doughty DG, et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005. (anchor RCT, n=93)
02Lintner K, Peschard O. Biologically active peptides: from a laboratory bench curiosity to a functional skin care product. Int J Cosmet Sci. 2000. (Sederma origin)
03Katayama K, et al. (Identification of the KTTKS collagen-stimulating sequence.) 1993.
04Jones RR, et al. Collagen-stimulating effect of peptide amphiphile C16-KTTKS on human fibroblasts. Mol Pharm. 2013. (PMID 23320752)
05He, Wang, Qu. (Peptide–cell-surface interactions in cosmetic peptides — review.) Front Pharmacol. 2023.
Updated 2026-07-20

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds
Argireline (Acetyl Hexapeptide-8)C
Peptide
GHK-Cu Peptide (Copper Tripeptide-1)B
Peptide
Palmitoyl Tripeptide-1 & Palmitoyl Tripeptide-5C
Peptide
SNAP-8 (Acetyl Octapeptide-3)C
Peptide
Explore by goal
Skin & aesthetic
Vallydia

A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.

RegionInternational
ExploreRegisterThe Register — full indexCategoriesTrust & COAHow we gradeOpen dataBrands
ShopCosmetic peptidesJournalQuizzes
TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.